Henry Schein, Inc. $HSIC Holdings Decreased by Wolf Hill Capital Management LP

Wolf Hill Capital Management LP lowered its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 2.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 485,938 shares of the company’s stock after selling 14,062 shares during the quarter. Henry Schein comprises about 3.0% of Wolf Hill Capital Management LP’s holdings, making the stock its 13th biggest position. Wolf Hill Capital Management LP’s holdings in Henry Schein were worth $32,252,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. CYBER HORNET ETFs LLC acquired a new stake in shares of Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein during the second quarter worth approximately $27,000. Sentry Investment Management LLC lifted its position in Henry Schein by 132.1% in the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock worth $59,000 after purchasing an additional 515 shares during the period. Evelyn Partners Investment Management Services Ltd acquired a new stake in Henry Schein in the second quarter worth approximately $62,000. Finally, Mather Group LLC. bought a new position in Henry Schein during the 3rd quarter valued at $71,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Buying and Selling

In other Henry Schein news, EVP Mark E. Mlotek sold 5,925 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the completion of the transaction, the executive vice president directly owned 80,554 shares in the company, valued at $6,508,763.20. This trade represents a 6.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Stanley M. Bergman sold 43,812 shares of Henry Schein stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the completion of the transaction, the chief executive officer directly owned 383,803 shares in the company, valued at approximately $31,207,021.93. This trade represents a 10.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 104,556 shares of company stock worth $8,476,351 in the last quarter. 1.08% of the stock is currently owned by corporate insiders.

Henry Schein Price Performance

Shares of NASDAQ:HSIC traded down $0.05 on Friday, reaching $74.92. 144,798 shares of the company traded hands, compared to its average volume of 1,413,771. The stock has a market capitalization of $8.59 billion, a PE ratio of 22.88, a P/E/G ratio of 2.26 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76. The company’s 50 day moving average is $78.24 and its 200-day moving average is $72.78. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. During the same period in the previous year, the firm posted $1.19 EPS. The company’s quarterly revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HSIC. Wells Fargo & Company lifted their price target on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. UBS Group raised their target price on Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Morgan Stanley lifted their target price on Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a report on Wednesday, February 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Finally, Barclays began coverage on shares of Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target for the company. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Henry Schein presently has a consensus rating of “Hold” and a consensus target price of $85.58.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.